RecruitingPhase 1NCT07226726

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Enrollment

20 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Congenital Myasthenic Syndrome

Summary

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AlloEx exosomes for people with congenital myasthenic syndrome. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAlloEx exosomes

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Locations(3)

Prodromos Stem Cell Institute

Naples, Florida, United States

Prodromos Stem Cell Institute

Irving, Texas, United States

Medical Surgical Associates Center

St John's, Antigua and Barbuda

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226726

Related Trials

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT0607855332 locations

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT064367429 locations

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

NCT014034021 location